GlassScriptPhysician profile
Mackenzie W Doshi
NPI 1588021257
$13,956.00
in general payments reported to CMS, 2019-2025
30 companies · $4,065 in 2025
The $4,065 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $889 · 2022: $2,035 · 2023: $2,985 · 2024: $3,983 · 2025: $4,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,633.14 |
| Education | $398.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,428.79 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,388.21 | 2021-2025 | |
| Genzyme Corporation | $1,177.44 | 2021-2025 | |
| Janssen Biotech, INC. | $1,149.00 | 2021-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $885.68 | 2022-2025 | Sotyktu |
| Pfizer INC. | $801.61 | 2021-2025 | |
| Incyte Corporation | $790.49 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $723.97 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $706.62 | 2023-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $691.31 | 2022-2025 | Dupixent, Libtayo |
| Ucb, INC. | $671.94 | 2021-2025 | Bimzelx |
| Lilly USA, LLC | $599.00 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $585.00 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Arcutis Biotherapeutics, INC. | $567.29 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $401.96 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $312.15 | 2025 | Vtama, Hadlima |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $202.76 | 2021-2025 | Cabtreo, Arazlo, Siliq |
| Amgen INC. | $162.00 | 2023-2025 | Otezla, Otezla |
| Almirall LLC | $129.05 | 2021-2025 | Klisyri |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.53 | 2023-2024 | Spevigo |
| Epi Health, LLC | $83.17 | 2022 | |
| Verrica Pharmaceuticals INC. | $77.44 | 2023-2024 | Ycanth |
| Sebela Pharmaceuticals INC. | $60.27 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $56.96 | 2024-2025 | Acthar |
| Journey Medical Corporation | $46.42 | 2022-2025 | |
| Kyowa Kirin, INC. | $23.41 | 2023 | Poteligeo |
| Nabriva Therapeutics, Plc | $17.00 | 2022 | |
| Vyne Pharmaceuticals INC. | $16.42 | 2021 | |
| Dermira, INC. | $16.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Doshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.